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Background: Malaria is a potentially severe disease widely distributed in tropical and subtropical regions
worldwide. Clinically, the progression of the disease can be life-threatening if it is not promptly diagnosed and
properly treated. Through treatment, the radical cure of Plasmodium vivax infection can be achieved, thus
preventing potential relapses and the emergence of new cases outside the Amazon region in Brazil. Surveillance
for therapeutic failure in non-endemic areas is advantageous, as it is unlikely that recurrence of the disease can
be attributed to a new malaria infection in these regions.
Methods: An observational study of 53 cases of P. vivax and mixed (P. vivax and Plasmodium falciparum) malaria
was conducted at a travel medicine centre between 2005 and 2011 in Rio de Janeiro and a descriptive analysis of
the potential factors related to recurrence of P. vivax malaria was performed. Groups with different therapeutic
responses were compared using survival analysis based on the length of time to recurrence and a set of
independent variables thought to be associated with recurrence.
Results: Twenty-one relapses (39.6%) of P. vivax malaria were observed. The overall median time to relapse,
obtained by the Kaplan-Meier method, was 108 days, and the survival analysis demonstrated an association
between non-weight-adjusted primaquine dosing and the occurrence of relapse (p< 0.03). Primaquine total dose
at 3.6 mg/kg gave improved results in preventing relapses.
Conclusions: A known challenge to individual cure and environmental control of malaria is the possibility of an
inappropriate, non-weight-based primaquine dosing, which should be considered a potential cause of P. vivax
malaria relapse. Indeed, the total dose of primaquine associated with non-occurrence of relapses was higher
than recommended by Brazilian guidelines.
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Malaria is a potentially severe disease widely distrib-
uted in tropical and subtropical regions worldwide.
Because of present-day ease of travel and the magni-
tude of migratory movements, it can be considered a
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reproduction in any medium, provided the orindividuals if the disease is not diagnosed in time
and treated appropriately. Most malaria cases in the
Americas occur in Brazil, where Plasmodium vivax
is responsible for 84% of the cases registered, 99.8%
of which occur in the Brazilian Amazon [1-3].
Relapse, a common feature of this type of malaria, is
defined as the reappearance of the disease and parasit-
aemia after initial eradication of blood forms. It is
caused by the survival of hypnozoites (dormant forms
of P. vivax or Plasmodium ovale latent in the liver) [4].
Although P. vivax malaria is known for its benign
course, there are reports of more complicated cases in
the Brazilian Amazon [5,6] and elsewhere [7,8].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of P. vivax by treatment can be due to several factors.
Although other factors – such as individual pharmacoki-
netic variations (poor absorption, rapid elimination or
low biotransformation of drugs), adherence to the treat-
ment, drug interactions, adverse drug events, dose
adjustment to body weight, and treatment duration –
are directly related to the infection’s response to anti-
malarial treatment, primaquine tolerance is a very
important issue that few studies have addressed [9,10].
Detection of treatment failure or relapse may prevent
malaria’s introduction into unaffected areas where the
vector remains a regional menace. As there is no stan-
dardized in vitro method for assessing the hypnozoitici-
dal effects of treatment, patient follow-up – particularly
outside the transmission areas – remains the best way to
monitor the susceptibility of P. vivax to primaquine.
This paper aims to describe the frequency of P. vivax
malaria relapse at a sentinel unit in a non-Amazonian
region and the factors potentially associated with this
event.
Methods
Study design, location, and patient selection
This descriptive study was conducted from January 2005
to October 2011 at a specialized post-travel care clinic
for adolescents and adults (≥12 years old) at the Insti-
tuto de Pesquisa Clínica Evandro Chagas (IPEC) in Rio
de Janeiro, a state located outside the Amazon region
and where malaria transmission does not occur.
Eighty-nine patients treated for vivax malaria during the
period were studied. Those who had returned to an area
of malaria transmission after starting treatment or who
had less than 28 days of follow-up were excluded. Accord-
ingly, the analysis contemplated 53 patients (59.6%). These
were followed up for 28 to 408 days (median= 62 days).
Of the 53 patients studied, 47 (88.7%) were infected
only with P. vivax, and the other six (11.3%), with
P. vivax and Plasmodium falciparum (mixed malaria).
Males predominated (75.5%), and ages ranged from 14
to 63 years (median = 29 years). Most of the travellers
came from South America: Brazilian Amazon (71.6%),
French Guiana (13.2%), Venezuela (3.8%), Guyana (1.9%)
and Suriname (1.9%); the rest were from Angola (3.8%)
and Indonesia (3.8%).
Plasmodium vivax infections were treated with
chloroquine (600 mg on the first day, 450 mg on
the second and third days) and primaquine. Mixed
infections caused by P. falciparum and P. vivax
were treated with mefloquine (20 mg/kg body
weight, single dose) and primaquine, a therapeutic
regimen still used by the Brazilian Malaria Therapy
Guidelines until 2009, or with artesunate +meflo-
quine (200 mg + 400 mg for three days) andprimaquine [11,12]. Primaquine was prescribed according
to the Brazilian Malaria Therapy Guidelines current at the
time of the malaria diagnosis and treatment: (1) total dose
of 3.5 mg/kg or fixed total dose of 210 mg regardless of
weight, following the 2001 guidelines [11]; or (2) dose
adjusted to stratified patient weight, with total dose ran-
ging from minimal 3.0 to maximal 3.4 mg/kg, following
the 2009 guidelines [12]. Over the entire study period,
during which both guidelines were used, the total dose of
primaquine ranged from 2.2 to 4.9 mg/kg. Primaquine
total dose was adjusted in 69.8% of treatments. Treatment
duration varied from 7 to 13 days (short regimen) or from
14 to 28 days (long regimen). A primaquine short regi-
men was prescribed in most of the treatments (66.0%)
and the remaining patients were treated with primaquine
long regimen. The choice of primaquine prescription regi-
men was made at doctors’ discretion at the outpatient
clinic. All medicines were prescribed for home use,
patients were educated on the importance of following
the prescribed regimen exactly and drug administration
was not supervised.
The project was approved by the IPEC Research
Ethics Committee, Fiocruz (No. 0031.0.009.000-10), and the
information obtained was kept strictly secret and confidential.
Detection and quantification of malaria parasites
Thin and thick blood smears were stained with Giemsa
and analysed by light microscopy using an immersion oil
lens (x100 objective magnification) to identify the para-
site species and determine the density of Plasmodium
asexual and sexual stages, according to standard proce-
dures [13]. Malaria smears were examined for diagnosis
at each follow-up visit until parasitological clearance and
at days 7, 14, 21, 28, 40, and 60 of treatment and at any
time in case of fever recurrence.
Data collection
Data were collected from the clinic and IPEC phar-
macovigilance databases. The variables considered were
(a) therapeutic response, classified as relapse or non-
relapse; (b) gender; (c) age; (d) adverse drug events;
(e) primaquine treatment duration; (f ) whether or not
the primaquine dose was weight-adjusted; (g) and prima-
quine total dose. Relapse was considered as the recur-
rence of parasitaemia following parasitological remission
after 28 days from starting treatment for vivax malaria.
Primaquine treatment duration was considered an indir-
ect factor related to adherence to treatment, since total
dose was the same, regardless of regimen.
Statistical analysis
Descriptive analysis was performed on factors potentially
related to relapse of P. vivax malaria. Groups with differ-
ent therapeutic responses were compared using survival
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days elapsed between starting treatment and
disease recurrence. The event of interest was relapse of
vivax malaria. Cases with no evidence of relapse during
the study period were censored at the last day of follow-
up. The Kaplan-Meier method was applied to calculate
the survival functions, which are defined as the probabil-
ity of relapse not occurring. The log-rank test was used
to compare survival functions among categories of each
variable. First the hazard ratios (HR) with 95% confi-
dence intervals were calculated, and then the Cox pro-
portional hazards model. Analysis of Schoenfeld and
Martingale residuals was used to assess the Cox method
assumptions for covariates of the adjusted model. The
smoothing function (spline) was applied for the non-
linear continuous variable “primaquine total dose” in
order to show the effect of dose on relapses graphically.
Spline coefficient values of less than zero indicate occur-
rence of protection against relapse. The significance level
for all hypothesis testing was set at p ≤ 0.05. Data were
analysed using R software, version 2.14.2.
Results
Twenty-one relapses (39.6%) of P. vivax malaria were
observed. Most (n = 14) occurred in patients from the
Brazilian Amazon; the other patients were from French
Guiana (n = 4), Venezuela (n = 2) and Indonesia (n = 1).
These relapses occurred in 45.7% of patients treated with
primaquine short regimen (N=35) and in 28.6% of
patients treated with primaquine long regimen (N= 14)
(p> 0.05). Thirty-two cases were censored in survival
analysis, because relapse did not occur during the
study period (Table 1). All patients with relapse were
re-treated. In one case, poor quality primaquine was
considered a potential cause of relapse, after more than
three relapses occurred in a short period of time. How-
ever, quality analysis (physical appearance, content and
dissolution) of the chloroquine and primaquine tablets
revealed no evidence of poor quality. Time to relapse
ranged from 29 to 369 days after start of treatment. In
survival analysis, overall median time to relapse obtained
by the Kaplan-Meier method was 108.0 days [95% CI
69 – not achieved], i.e., 50% of relapses occurred less
than 108 days after start of treatment (Figure 1). Patients
with adjusted doses of primaquine had higher survival
and, consequently, lower relapse rate (p< 0.03) than
those with no body weight-based dosing adjustments
(Figure 2). The other covariates analysed were not statis-
tically significant (Table 1). The risk of relapse, calculated
by the Cox proportional hazards model, was 2.94 times
greater [95% CI 1.09 - 8.33] for patients with no dosing
adjustments than for patients with dosing adjustments;
and, after adjustment for covariables (gender, age and
primaquine treatment duration), estimated risk of relapsewere 3.13 [95% CI 1.08-9.09] (Table 2). Primaquine total
dose of 3.6 mg/kg gave superior results in preventing
relapses (protection factor). The probability of relapse
not occurring, when primaquine total dose ranged from
3.6 to 4.1 mg/kg, is shown graphically (Figure 3). The
increased risk of relapse with primaquine total dose
lower than 3.6 mg/kg in relation to doses ranging from
3.6 to 4.1 mg/kg was statistically significant. The esti-
mated risk adjusted for covariables was 9.36 [1.06-82.23].
Both Cox proportional hazards models returned strong
concordance, with values higher than 70% (Table 2).
Discussion
The current study, performed in the city of Rio de
Janeiro, where malaria transmission does not occur,
showed that approximately 40% of patients treated
within the last six years had relapses of P. vivax malaria
and that failure to adjust primaquine dosing was the
most important factor in the occurrence of relapse. Still,
the primaquine total dose related to non-occurrence of
relapse was higher than recommended by the Brazilian
guidelines. Relapse is considered to be the parasitological
recurrence of P. vivax after 28 days of treatment in
patients who do not return to an endemic area [4]. Non-
endemic areas, therefore, offer advantages for monitor-
ing therapeutic failures due to improper treatment
or drug resistance since risk of re-infection is minimal
or absent.
A retrospective study in São Paulo, Brazil [14] among
1,347 cases of P. vivax malaria showed a relapse rate of
25% over seven years. However, Duarte et al [15] in
Cuiaba, Brazil and Kitchener et al [16] in Melbourne,
Australia, prospectively followed patients for two years
and showed relapse rates of 14% in 50 patients and 24%
in 318 patients, respectively. The higher frequency
recorded (40%) could be explained by the smaller sample
in this study or by the fact that data for Brazil obtained
in 2005-2011 were compared to data obtained in 1991
and in 2003, and concern with primaquine tolerance
may have been different in these two periods. The data
reported by Kitchener in Australia certainly refer to
patients who acquired malaria in quite different local-
ities, and the situations may not be comparable to data
obtained in Brazil.
Relapses can occur months or even years after the
time of initial infection, with a maximum recorded time
of four years [17-20]. In the present study, 86% of
relapses occurred up to day 180 after start of treatment,
in agreement with the study by Boulos [14], where 95%
of relapses took place before day 180, and the longest
time to relapse (369 days) occurred in a patient with a
P. vivax infection acquired on a trip to Indonesia, where
the prevalence of primaquine-tolerant P. vivax is higher
than elsewhere [21]. Although there is no standardized or
Table 1 Patients with P. vivax or mixed (P. vivax and P. falciparum) malaria treated at IPEC (2005-2011), classified
according to therapeutic response
Non-Relapse Relapse Median [CI 95%] (days) p (Log-Rank)
n % N %
Sample 32 100 21 100 108 [69-NA}
Gender
Men 22 68.8 18 85.7 104 [68-NA] 0.16
Women 10 31.2 3 14.3 NA [58-NA]
Age range (years)
14-30 14 43.8 14 66.7 79 [58-NA] 0.22
31-50 13 40.6 4 19.0 369 [108-NA]
≥51 5 15.6 3 14.3 68 [51-NA]
Adverse drugs events (ADE)*
Yes 10 31.3 2 9.5 NA [58-NA] 0.20
No 17 53.1 12 57.1 108 [68-NA]
Duration of primaquine therapy*
Short regimen 19 59.4 16 76.2 79 [65-NA] 0.34
Long regimen 10 31.3 4 19.0 218 [104-NA]
Primaquine total dose adjusted by weight*
Yes (≥ 3.2 mg/kg) 25 78.1 12 57.1 182 [104-NA] 0.03
No (< 3.2 mg/kg) 5 15.6 6 28.3 54 [40-NA]
* Missing data was 22.6%, 7.5% and 9.4% for ADE, duration of treatment with primaquine and primaquine dose adjusted by weight, respectively.
NA = not achieved.
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[9], the demonstration of primaquine-tolerant P. vivax
in the South Pacific, Southeast Asia, Western Pacific,
Oceania and Central America [9,10,21,22], associated with































Figure 1 Survival curve. Overall Kaplan-Meier survival curve for
P. vivax malaria relapse among patients included in the study (IPEC,
2005-2011). Survival function is defined as the probability of relapse
not occurring.possibility of tolerance being introduced into the Brazilian
Amazon [23], from where most relapse cases came.
Besides drug resistance, other factors, such as adherence
to the treatment, treatment duration, quality of anti-
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Figure 2 Survival curve by adjusted dose of primaquine.
Patients with adjusted doses of primaquine had a higher survival
and, consequently, lower relapse rate (p< 0.03) than those with
doses not adjusted for patient body weight. IPEC, 2005-2011.
Table 2 Crude and adjusted hazard ratio (HRs) for potential factors related to relapse of P. vivax malaria
Crude (n = 53) Adjusted* (n = 48)
Model 1 Model 2
HR [CI 95%] p (Wald) HR [CI 95%] p (Wald) HR [CI 95%] p (Wald)
Gender
Men 2.36 [0.69–8.07] 0.17 2.23 [0.63-7.84] 0.21 3.9 [0.59-26.81] 0.16
Women 1 1 1
Age (years) ** 0.97 [0.93-1.02] 0.25 0.95 [0.90-1.01] 0.09 0.94 [0.89-0.99] 0.03
Adverse drug events (ADE)
Yes 0.39 [0.09-1.74] 0.22 - - - -
No 1 - - - -
Duration of primaquine therapy
Short regimen 1 0.18 1 0.14 1 0.04
Long regimen 0.46 [0.15-1.42] 0.42 [0.13-1.33] 0.28 [0.08-0.98]
Primaquine total dose adjusted by weight
Yes (≥ 3.2 mg/kg) 1 0.03 1 0.04 - -
No (< 3.2 mg/kg) 2.94 [1.09-8.33] 3.13 [1.08-9.09] - -
Primaquine total dose (mg/kg)
< 3.6 5.24 [0.68-40.15] 0.24 - - 9.36 [1.06-82.23] 0.04
3.6 – 4.1 1 - - 1
> 4.1 7.09 [0.64-78.74] - - 15.4 [0.79-300.57] 0.07
Concordance - - 0.73 0.75
R square - - 0.23 0.28
p (Wald) - - 0.06 0.08
* Cox regression models. **Continuous variable.
Pedro et al. Malaria Journal 2012, 11:245 Page 5 of 7
http://www.malariajournal.com/content/11/1/245body weight may be related to the infection’s response to
anti-malarial treatment.
Adherence to anti-malarial treatment remains an im-
portant key to malaria control [24,25]. Direct methods
(drug serum levels and supervised treatment), and indir-
ect methods (interviews) can quantify adherence to
treatment. Although supervision is directly related to
treatment effectiveness, health education generally tends
to approximate the efficacy of non-supervised and
supervised treatments [26,27]. Patients at IPEC are edu-
cated on the importance of adherence to regular therapy.
This procedure resulted in high adherence behaviour, as
previously demonstrated [28] by using Morisky’s assess-
ment protocol [29].
Anti-malarials’ quality ensures their therapeutic effect-
iveness in eliminating parasites from the blood and
achieving malaria treatment success. Studies performed
in Brazil indicate that poor quality anti-malarial drugs
and inappropriate storage conditions may contribute
to the development of parasite resistance [30,31]. In
the present study, poor quality primaquine was sus-
pected as a potential cause of relapse after four relapses
in a short time, three of them in one patient, after
treatment with the same batch of primaquine [32].
Impaired drug quality was discounted, however, and thepatient was successfully treated after adjusting the dose
of primaquine.
Most adverse drug reactions were mild and involved
disorders of the gastrointestinal system – nausea, vomit-
ing and diarrhoea, which could theoretically have
reduced drug absorption. However, in the applied model,
relapses were not associated with the occurrence of ad-
verse drug reactions in the study.
Primaquine is currently the only drug available for treat-
ment of the latent liver forms of the parasite.
The literature suggests that a 14-day course of primaquine
may be more effective than a 7-day course, and this super-
iority may be attributable to significant accumulation of
the drug’s active metabolite after longer administration
[33-35]. On the other hand, more prolonged treatment
may hinder patient adherence, as clinical cure usually
occurs in less than 72 hours [28,36]. It seems, however,
that this did not occur in the current study, since the pro-
portion of relapses after long-regimen treatment was
lower than after the short regimen (p> 0.05) and patient
adherence rates were high [28].
Conversely, the results clearly indicate an association
between non-weight-based primaquine dosing and the
occurrence of relapses (p< 0.03). These results agree with
studies that suggested dosing adjustments for patients
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Figure 3 Smoothing function (spline) for primaquine total dose
by weight. Primaquine total dose ranging from 3.6 to 4.1 mg/kg
seems to offer protection against relapse.
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global problem [37-40].
Although it is already known that weight-based dosing
of primaquine is required to prevent relapses, it is
important that an appropriate weight-based primaquine
total dose be determined and confirmed to guide clinical
decisions. In this study, a total dose of 3.2 mg/kg indicates
protection against relapses. However, the probability of re-
lapse occurring still exists given the upper limit of the
confidence interval. Therefore, in order to treat the
patients in this study more effectively, a more appropriate
dose would be higher (between 3.6 and 4.1 mg/kg) than
the one recommended by the Brazilian Ministry Health
(from 3.0 to 3.4 mg/kg [11,12]). The more effective dose
range demonstrated here is also closer to the World
Health Organization’s recommendation of 3.5 mg/kg in
14 days for radical cure of vivax malaria [41]. This dose
does not apply to individuals infected in countries from
Oceania and Southeast Asia, where the total recom-
mended dose is 6.0 - 7.0 mg/kg in 14 days [42-44]. The
increased risk of relapse foreseen by the smoothing func-
tion (spline) above 4.1 mg/kg primaquine total dose by
weight, as shown in Figure 3, was not statistically
significant.
Although small sample size may be considered a limita-
tion on the statistical analysis, an association was found
between adjusted primaquine dose and protection against
relapse. Also, follow-up of infected patients in non-
endemic areas is a good methodological approach to
define a true relapse, because no confounding re-infection
is possible in such areas.The results reported here corroborate the conclusion
of Fernando et al [45] that there is enough evidence to
support the use of higher total doses of primaquine to
prevent relapses in weight-adjusted treatment.
Conclusions
The study suggests that the total dose of primaquine
above which relapses do not occur is 3.6 mg/kg. This
conclusion is in agreement with WHO and other inter-
national guidelines, but is higher than the total dose
recommended by Brazilian Ministry of Health Guide-
lines. Given the ease of travel, the evidence of growing
primaquine tolerance around the world and the possibil-
ity of its introduction into the Amazon basin, it would
be advisable to review the recommendations of the
Brazilian Malaria Control Programme. Finally, it may be
argued that malaria control programmes should use
public health educational messaging campaigns to alert
travel clinicians to the fact that risk of therapeutic failure
can be reduced by tailoring drug therapies individually
to each patient.
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